171 related articles for article (PubMed ID: 23199477)
1. Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists.
Yamamoto S; Kobayashi H; Kaku T; Aikawa K; Hara T; Yamaoka M; Kanzaki N; Hasuoka A; Baba A; Ito M
Bioorg Med Chem; 2013 Jan; 21(1):70-83. PubMed ID: 23199477
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists.
Yamamoto S; Tomita N; Suzuki Y; Suzaki T; Kaku T; Hara T; Yamaoka M; Kanzaki N; Hasuoka A; Baba A; Ito M
Bioorg Med Chem; 2012 Apr; 20(7):2338-52. PubMed ID: 22391033
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists.
Yamamoto S; Matsunaga N; Hitaka T; Yamada M; Hara T; Miyazaki J; Santou T; Kusaka M; Yamaoka M; Kanzaki N; Furuya S; Tasaka A; Hamamura K; Ito M
Bioorg Med Chem; 2012 Jan; 20(1):422-34. PubMed ID: 22094279
[TBL] [Abstract][Full Text] [Related]
4. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
5. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor antagonists for prostate cancer therapy.
Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
[TBL] [Abstract][Full Text] [Related]
7. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
8. A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.
Guerrini A; Tesei A; Ferroni C; Paganelli G; Zamagni A; Carloni S; Di Donato M; Castoria G; Leonetti C; Porru M; De Cesare M; Zaffaroni N; Beretta GL; Del Rio A; Varchi G
J Med Chem; 2014 Sep; 57(17):7263-79. PubMed ID: 25121586
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer.
Yoshino H; Sato H; Shiraishi T; Tachibana K; Emura T; Honma A; Ishikura N; Tsunenari T; Watanabe M; Nishimoto A; Nakamura R; Nakagawa T; Ohta M; Takata N; Furumoto K; Kimura K; Kawata H
Bioorg Med Chem; 2010 Dec; 18(23):8150-7. PubMed ID: 21050768
[TBL] [Abstract][Full Text] [Related]
10. 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.
Saito Y; Mizokami A; Tsurimoto H; Izumi K; Goto M; Nakagawa-Goto K
Eur J Med Chem; 2018 Sep; 157():1143-1152. PubMed ID: 30189396
[TBL] [Abstract][Full Text] [Related]
11. In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer.
Shen HC; Shanmugasundaram K; Simon NI; Cai C; Wang H; Chen S; Balk SP; Rigby AC
Mol Endocrinol; 2012 Nov; 26(11):1836-46. PubMed ID: 23023563
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists.
Inoue K; Urushibara K; Kanai M; Yura K; Fujii S; Ishigami-Yuasa M; Hashimoto Y; Mori S; Kawachi E; Matsumura M; Hirano T; Kagechika H; Tanatani A
Eur J Med Chem; 2015 Sep; 102():310-9. PubMed ID: 26295173
[TBL] [Abstract][Full Text] [Related]
13. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
14. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
15. 20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.
Fousteris MA; Schubert U; Roell D; Roediger J; Bailis N; Nikolaropoulos SS; Baniahmad A; Giannis A
Bioorg Med Chem; 2010 Oct; 18(19):6960-9. PubMed ID: 20826091
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
[TBL] [Abstract][Full Text] [Related]
17. Steroid derivatives as pure antagonists of the androgen receptor.
Gauthier S; Martel C; Labrie F
J Steroid Biochem Mol Biol; 2012 Oct; 132(1-2):93-104. PubMed ID: 22449547
[TBL] [Abstract][Full Text] [Related]
18. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.
Mitsiades N
Cancer Res; 2013 Aug; 73(15):4599-605. PubMed ID: 23887973
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor antagonists: a patent review (2008-2011).
Mohler ML; Coss CC; Duke CB; Patil SA; Miller DD; Dalton JT
Expert Opin Ther Pat; 2012 May; 22(5):541-65. PubMed ID: 22583332
[TBL] [Abstract][Full Text] [Related]
20. SAR based design of nicotinamides as a novel class of androgen receptor antagonists for prostate cancer.
Yang SH; Song CH; Van HT; Park E; Khadka DB; Gong EY; Lee K; Cho WJ
J Med Chem; 2013 Apr; 56(8):3414-8. PubMed ID: 23527816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]